Trial Condition(s):

Gastrointestinal stromal tumors

Regorafenib post-marketing surveillance in Japan

Bayer Identifier:

16732

ClinicalTrials.gov Identifier:

NCT01933958

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Inclusion Criteria
- Patients who are treated with Regorafenib/ STIVARGA and meet the product label.
Exclusion Criteria
- Patients who are treated with Regorafenib/ STIVARGA and don’t meet the product label.

Trial Summary

Enrollment Goal
72
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Stivarga (Regorafenib, BAY73-4506)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design